obrixtamig + topotecan

Obrixtamig + topotecan is a combination therapy for advanced small cell lung cancer (SCLC), currently under clinical investigation. **Obrixtamig (BI 764532, OBT-620)** is a bispecific T-cell engager antibody that binds to both **delta-like ligand 3 (DLL3)** on tumor cells and **CD3** on T cells, facilitating T cell-mediated cytotoxicity against DLL3-expressing cancer cells, such as in SCLC. **Topotecan** is a topoisomerase I inhibitor, a chemotherapeutic agent approved for treatment of relapsed SCLC. Early-phase clinical trial data suggest that the combination demonstrates manageable safety and promising efficacy in patients with extensive-stage SCLC who have progressed after first-line therapy. Obrixtamig was developed by Boehringer Ingelheim and acts to redirect T cells to kill DLL3-expressing tumor cells, while topotecan induces cytotoxicity via inhibition of DNA replication and repair[1][2][4][5][6][7].

Other names

obrixtamig + topotecanBI 764532 + single agent chemotherapy